Key Highlights

  • Total Revenue reached 339 million euros, more than doubling year over year, though it missed the 376 million euro estimate by 9.94 percent, while adjusted EPS of 2.83 euros beat the 0.78 euro estimate by 262.82 percent.
  • YORVIPATH generated 252 million euros in quarterly revenue, reaching blockbuster status on a run-rate basis in just its second year on the market.
  • UBEGLA, the company's newly launched achondroplasia treatment, generated 8 million euros in its first partial quarter, with more than 220 U.S. enrollments and over 65 percent reimbursement approval by late July.
  • The company reaffirmed its Vision 2030 target of 5 billion euros in annual revenue and now expects more than 500 million euros in Operating Cash Flow for 2026.

YORVIPATH Anchors a Doubling of Total Revenue

Ascendis Pharma A/S (NASDAQ:ASND) reported total revenue of 339 million euros for the second quarter, more than doubling from the prior-year period, with product revenue of 315 million euros driven overwhelmingly by continued uptake of YORVIPATH, the company's treatment for adult hypoparathyroidism. YORVIPATH revenue reached 252 million euros in the quarter, and management said the drug has reached blockbuster status on a run-rate basis in just its second year of commercial availability, now sold in more than 35 countries.

The result missed the average revenue estimate, a gap management attributed in part to the inherent difficulty forecasting Demand for a still-scaling rare disease therapy rather than any weakening in underlying patient uptake. New patient enrollment in the U.S. remained described as robust and consistent with prior quarters, with high treatment retention rates cited as evidence of patient satisfaction, though the company continues to avoid providing specific prescription Volume figures beyond describing enrollment as steady at roughly 1,000 new U.S. patients per quarter.

UBEGLA Launch Shows Early Signs of Market Expansion

UBEGLA, Ascendis' newly launched treatment for achondroplasia, generated 8 million euros in revenue during its first partial quarter on the market, with enrollment continuing to accelerate to more than 220 unique U.S. patients by late July and over 65 percent already approved for reimbursement. Management described uptake as coming from a broad mix of patients, including those switching from existing therapy, those returning to treatment after previously discontinuing it, and those trying pharmacological treatment for achondroplasia for the first time.

That last category is what executives pointed to as evidence the product is expanding the overall treatable market rather than simply capturing share from an existing competitor. The company continues to face unresolved intellectual property litigation related to UBEGLA, with an initial opinion from a single judge in an ongoing case expected in August and further proceedings continuing into December, though management maintained that even an unfavorable outcome would not materially disrupt the company's broader growth trajectory given the product's approval status outside the U.S. and the public interest considerations at play.

Pipeline Investment Continues Alongside Rising Commercial Spend

Research and development expenses rose to 76 million euros from 59 million euros in the prior quarter, reflecting continued investment in the company's broader TransCon technology pipeline, including a Phase 3 combination trial in achondroplasia set to begin enrollment later this year. SG&A expenses increased to 173 million euros as the company continues to invest in commercial infrastructure supporting the YORVIPATH and UBEGLA launches.

Despite the step-up in spending, operating profit for the quarter included 158 million euros of other Operating Income tied to the sale of a priority review voucher, helping non-IFRS Operating Margin reach 27 percent. The company ended the quarter with 812 million euros in cash and no bank or convertible Debt following the settlement of its outstanding convertible notes, providing Balance Sheet flexibility to continue funding the pipeline expansion without near-term financing pressure.

Long-Term Targets Reaffirmed Despite Near-Term Estimate Miss

Management reaffirmed its belief that the Business remains on track toward its Vision 2030 target of 5 billion euros in annual revenue and reiterated confidence in eventually exceeding 10 billion euros in revenue over the following decade as additional TransCon-based products reach the market. The company raised its full-year operating cash flow guidance to more than 500 million euros, up from a similar unbounded target discussed earlier in the year, reflecting the benefit of the priority review voucher sale alongside underlying commercial growth. Execution risk remains tied to the pace of YORVIPATH's continued international rollout, the durability of UBEGLA's early enrollment trends beyond its initial launch window, and the eventual resolution of ongoing Patent litigation, though management characterized none of these as likely to alter the company's Long-term Growth trajectory.